HPV Vaccine: Adult Catch-Up

Screening · §124

If you missed the HPV shot as a teenager, the FDA approved you for it through age 45 in 2018 — but the CDC stopped short of calling it routine, instead telling clinicians to "have a conversation." The catch: even after years of sexual activity, you are probably still naive to most of the nine HPV types the vaccine covers, and the catch-up trial in adults 24–45 hit 88.7% efficacy against vaccine-type pre-cancer and warts. The payoff is six cancers prevented at the long horizon, no genital warts at the short one, and three sore arms in between. Whether the math works for you depends on what your next decade of partner exposure looks like.

Decide · Course Evidence Moderate Chapter Screening

A bounded course: three shots over six months, then done forever. The list price stings if you are uninsured (~$1,089), but commercial insurance usually covers it. The longevity payoff is real but smaller than vaccinating at 12 — most of the lifetime exposure has already happened. The decision turns on one question: how much new sexual exposure is plausibly ahead of you?

The vaccine teaches your immune system to recognise the outside of nine HPV strains — six that cause most cervical, anal, throat, and other HPV-driven cancers, and two more that cause about 90% of genital warts. It is a shell, not the virus: no DNA inside, no chance of giving you HPV. The shell looks enough like the real virus that you build antibodies that swarm any actual HPV particle before it can get into your cells.

The thing that surprises people about catch-up: this is not "either you were exposed or you weren't." It is type-by-type. There are nine strains in the vaccine, and you have to have already caught a specific strain for the vaccine to do nothing about that strain. Most adults, even with a long partner history, are still naive to most of the nine — the per-encounter, type-specific transmission rate is the relevant unit, not your total number of partners. The vaccine cannot clear an infection you already have. It cannot erase warts you already have. It can only block the strains you have not picked up yet, which for most people is still most of them.

Does it actually work this late?

Yes — the catch-up evidence is the best part of the case. The pivotal adult trial randomised 3,819 women aged 24–45 and tracked them for four years. Among the ones who completed the series and were naive to the vaccine strains going in, the vaccine prevented 88.7% of vaccine-type pre-cancer and genital lesions and roughly 99% of vaccine-type genital warts. The number drops to about 47% if you include the women who were already infected when they enrolled — which is exactly what a prophylactic shot looks like: it cannot rescue strains you already carry, only block the rest.

At population scale, the Swedish national register followed 1.67 million women and found cervical cancer rates dropped by 63% in vaccinated women overall — and by nearly 88% in the ones vaccinated before age 17 Lei et al. 2020. The England programme analysis found the same pattern: huge effect in the youngest cohorts, real-but-smaller effect in the older catch-up cohorts Falcaro et al. 2021. For men, the cleanest direct trial enrolled men who have sex with men and showed the vaccine prevented 75% of anal pre-cancer caused by vaccine strains Palefsky 2011. A 2024 US cohort comparing vaccinated to unvaccinated adults under 40 found HPV-related cancers in vaccinated men dropped by more than half, driven mostly by head-and-neck cancers Saxena et al. 2024.

One trial points the other way and is worth naming. In HIV-positive adults aged 27+, the vaccine failed to prevent new anal HPV infection — the population with the highest baseline cancer risk, where you would predict the biggest benefit, got none Wilkin 2018. The likely reason: by 27, this group's cumulative exposure to most of the nine strains was already too high for "block the rest" to leave much rest. That is the catch-up question in miniature — how much of your lifetime exposure is already behind you.

What you are actually preventing

The cancers HPV causes do not lurk in the corners of medicine. Cervical cancer kills more than 4,000 American women a year. Throat cancer is the fastest-rising cancer in middle-aged American men and HPV is the engine behind it — incidence is still climbing, with the peak burden projected for the mid-2030s Damgacioglu 2022. Anal cancer, vulvar cancer, vaginal cancer, penile cancer — they are individually rarer but they all run on the same handful of HPV strains, and one shot programme covers all of them.

The thing you might catch first, though, is genital warts. They are not subtle. They show up months after exposure, they require burning or freezing or cutting off, and they come back. Annual incidence is roughly one in a hundred sexually active adults. The vaccine prevents the strains that cause about 90% of them Castellsague 2011.

The honest reframe: the cancer payoff is large in absolute terms over the decades but the marginal payoff from getting vaccinated at 35 instead of 12 is smaller — because much of the lifetime exposure has already happened. Throat cancer in men is the partial exception. That clock runs 20–30 years from exposure to diagnosis, and if you are 35 a lot of that window is still ahead of you.

Who this is most worth it for

The case sharpens at the edges. If any of the following describes your next decade, the math leans toward yes:

You are newly single, recently divorced, or about to be — new partners ahead means new strain exposure ahead.
You are a man who has sex with men. Baseline anal-cancer risk is many times the population average, and the vaccine is the only prevention tool that exists.
You are about to go on immunosuppression — pre-transplant, planned chemo, an autoimmune regimen — and want the antibody response while your immune system can still build one.
Your partner count to date has been low, which makes you more likely to still be naive to most of the nine strains.

The case dulls if you are in a long-term mutually monogamous relationship with no new exposure plausibly ahead, or if you have had documented HPV-related disease from multiple vaccine strains and the room left for "block the rest" has shrunk.

How to get it

Walk into a primary-care office or a pharmacy. The whole programme is three quick injections in the upper arm at month 0, month 2, and month 6. Pharmacies in most states administer it without a doctor's referral. If you miss a dose, you do not restart — you just complete the series late. There is no booster after the three doses.

What it costs

The list price is roughly $363 per shot, about $1,089 for the full series — that is the number you face if you walk in uninsured at full retail. Almost every US commercial insurance plan covers Gardasil 9 with no copay; Medicare Part D usually covers it. The catch in the catch-up band is that ACA preventive-care coverage is mandated only through age 26 — past that, payers vary, some require a documented clinical indication, and a phone call to your insurer before booking is worth its weight. Merck runs a patient-assistance programme that gives the vaccine free to uninsured adults 19–45 meeting income criteria.

When not to

Where this goes wrong

Three failure patterns are common. People start the series and never finish — life gets in the way and dose three slips. Two doses confer noticeably less protection than three in this age group; the two-dose adolescent schedule is not validated past 14. Set the dose-three calendar reminder when you book dose one.

People get the shot, breathe a sigh of relief, and stop getting cervical screening. Do not. The vaccine prevents about 90% of HPV-driven cancer — not 100% — and the remaining strains still cause disease that Pap and HPV co-testing catch early CDC 2024.

People expect the shot to treat something they already have. It does not. If you have visible warts, an abnormal Pap, or a known HPV-positive lesion, vaccination does not treat those — and it will not make the existing strain go away. It will still protect against the other vaccine strains you have not picked up yet, which is usually most of them.

What changes after you finish

The fastest payoff lands inside weeks of dose three: your odds of catching new genital warts from a partner go to essentially zero for the two strains that cause about 90% of them Castellsague 2011. You will not feel this — you just stop being in the lottery for a problem that turns Tuesdays into dermatology appointments.

The cervical-screening payoff shows up in the 5-to-10-year window: fewer abnormal Paps, fewer colposcopies, fewer LEEP procedures to cut out pre-cancer Falcaro et al. 2021. The actual cancers — cervical, anal, throat, the rarer ones — take 15 to 30 years to show their reduced rates, and for throat cancer in men the population-level signal will not be visible in registry data until the mid-2030s Damgacioglu 2022. You do not see this one as it happens. The version of you at 60 just does not get the diagnosis the unvaccinated version did.

What to look at next

Cervical cancer screening (Pap and HPV co-testing) remains your job vaccinated or not — different substance, separate decision. Anal cancer screening becomes worth discussing if you are a man who has sex with men or living with HIV. If you have HPV-related lesions today, you are looking at treatment, not prevention — the vaccine does not heal what is already there.

Related in the handbook

Helps

— The shot blocks the virus; screening catches what slips through — you want both, not one.

— The shot prevents the HPV cancers; the screening schedule is how you catch the ones it can't fully cover — they work as a pair.
— This is the adult catch-up version of a shot most people miss — it slots into the broader vaccine schedule.
— If you're catching up on HPV, check whether the shingles and RSV shots are due too — both are big.

Substance + claimed effects

The HPV vaccine for adults aged 27–45 — almost always Gardasil 9 (9vHPV) in the United States and most high-income markets — is the routine adolescent immunisation given late. It targets nine human papillomavirus types: HPV-6 and -11 (cause ~90% of genital warts) and HPV-16, -18, -31, -33, -45, -52, -58 (cause ~90% of HPV-attributable cancers — cervical, anal, oropharyngeal, vulvar, vaginal, and penile). The schedule for anyone starting at age 15 or older is three intramuscular doses at 0, 1–2, and 6 months CDC 2024. The FDA expanded the licensed age range to 45 in October 2018 FDA 2018; ACIP did not issue a routine catch-up recommendation but instead authorised shared clinical decision-making for unvaccinated adults in this band Meites 2019. Claimed effects covered by this entry: reduced risk of cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, and of anogenital warts, in adults who missed routine vaccination. Effects scale with how naive the recipient is to vaccine HPV types — the vaccine is prophylactic, not therapeutic, against existing infection.

Evidence by addressing question

Mechanism

The vaccine is a non-infectious virus-like particle (VLP) preparation: recombinant L1 capsid proteins self-assemble into empty capsids that mimic the surface of HPV but carry no viral DNA. Intramuscular delivery with an aluminium adjuvant produces serum neutralising antibody titres an order of magnitude higher than natural infection. Antibody transudates across the genital and oral mucosa and binds incoming virions before they can establish basal-keratinocyte infection. Mechanism is purely prophylactic: the vaccine cannot clear an established infection, eliminate prevalent lesions, or treat existing warts. This is why the catch-up benefit hinges on type-specific naivety — even sexually experienced adults are typically naive to most of the nine vaccine types, because per-encounter type-specific transmission is the relevant unit, not cumulative sexual exposure Meites 2019.

Evidence

The pivotal adult catch-up trial is the Castellsague quadrivalent study in 3,819 women aged 24–45 with no history of cervical disease or genital warts Castellsague 2011. Per-protocol efficacy against the combined endpoint of persistent HPV-6/11/16/18 infection plus related CIN/EGL was 88.7% (95% CI 78.1–94.8) over a median 4 years. The intention-to-treat analysis — which includes women with prevalent infection at baseline — dropped to ~47%, exactly as expected for a prophylactic agent. Genital-wart prevention reached ~99% type-specific in the same population. The 9-valent extension trial in 14,215 women (Joura) added efficacy of 96.7% against HPV-31/33/45/52/58-related high-grade cervical/vulvar/vaginal disease, with comparable HPV-6/11/16/18 efficacy to the quadrivalent Joura 2015.

Direct cancer-endpoint evidence comes from population registers and modern target-trial emulations. The Swedish nationwide cohort (1,672,983 girls and women 10–30) found cervical cancer incidence rate ratio 0.37 (95% CI 0.21–0.57) after adjustment, with the strongest effect when vaccinated before age 17 (~88% reduction) and a meaningful but smaller effect when vaccinated at 17–30 (~53% reduction) Lei et al. 2020. The England programme analysis showed an 87% cervical-cancer reduction in cohorts vaccinated at 12–13 and progressively smaller — but still substantial — reductions in older catch-up cohorts Falcaro et al. 2021. A 2024 TriNetX retrospective cohort in vaccinated vs unvaccinated US adults under 40 reported an odds ratio of 0.46 (95% CI 0.29–0.72) for any HPV-related cancer in males, driven primarily by head-and-neck cancers (OR 0.44) Saxena et al. 2024.

For non-cervical sites: the Palefsky trial in 602 MSM aged 16–26 showed 74.9% per-protocol efficacy against HPV-6/11/16/18 anal intraepithelial neoplasia grade 2/3 and ~95% against the anal infection endpoint Palefsky 2011. For oropharyngeal cancer there is no completed RCT — the disease has a ~30-year lag between exposure and diagnosis — but modelling, immunogenicity studies showing oral neutralising antibody, and the male HPV-related cancer reductions in Saxena 2024 form a convergent indirect case. Damgacioglu projected that current US vaccination uptake will not reduce male oropharyngeal cancer rates until the mid-2030s, with the peak burden still ahead Damgacioglu 2022.

The hard signal pointing the other way: the AIDS Clinical Trials Group A5298 RCT enrolled HIV-positive adults aged 27+ and found no prevention of new anal HPV infection or improvement of anal HSIL outcomes Wilkin 2018. The trial did suggest a protective signal for oral HPV. This is the load-bearing limitation of the catch-up window: when the population's lifetime cumulative type-specific exposure is high (as in HIV-positive MSM with extensive sexual history), the marginal naive-type benefit shrinks toward zero. It does not shrink to zero for adults whose risk profile resembles the Castellsague enrollee.

Protocol

Three doses at 0, 1–2, and 6 months for anyone starting at ≥15 years (the two-dose schedule applies only when the series began at 9–14) CDC 2024. Intramuscular, deltoid or anterolateral thigh. No serology screening before vaccination — it is not cost-effective and does not change the recommendation: even if seropositive for one type, a recipient remains naive to the others. There is no recommended booster after the three-dose primary series for immunocompetent adults; long-term follow-up of the original adolescent cohorts shows sustained antibody and protection at 10+ years.

Contraindications

Yeast hypersensitivity (the vaccine is produced in Saccharomyces cerevisiae) and prior severe reaction to a prior HPV dose are the only absolute contraindications. Pregnancy: defer until after delivery — not because of a known harm signal, but because the vaccine has not been studied in pregnancy and registry data are reassuring rather than definitive. Breastfeeding is not a contraindication. Moderate or severe acute illness is a temporary defer. Immunocompromise (including HIV, solid organ transplant, ongoing chemotherapy) is not a contraindication but the three-dose schedule applies and seroconversion rates are lower; clinical benefit in this population is less well-established Wilkin 2018.

Misconceptions

Three patterns dominate. First, "I'm already sexually active so it's too late" — false; type-specific naivety is the relevant unit, and even adults with extensive sexual histories are usually naive to most of the nine vaccine types. Second, "If I was vaccinated with the bivalent or quadrivalent vaccine years ago, I don't need 9-valent" — broadly true at the population level (existing protection covers the highest-risk types), but a supplemental 9-valent series is permissible if a clinician and patient decide the broader coverage is worth it; ACIP does not recommend routine revaccination. Third, "the vaccine treats existing warts or HPV-positive Pap results" — false; it is purely prophylactic and has no therapeutic effect on established lesions or active infection.

Audience

Catch-up benefit is largest for adults with new or anticipated partner exposure, men who have sex with men (high anal cancer baseline), individuals with anticipated immunosuppression (transplant candidates), and those with limited prior partner counts who remain plausibly type-naive. Catch-up benefit is smallest for adults in long-term monogamous relationships with no new exposure anticipated, and for HIV-positive adults with established multi-type infection Wilkin 2018. Sex: the absolute cervical-cancer reduction is the largest single benefit per dose in women; the largest growing cancer prevented in men is oropharyngeal, but the time horizon is decades Damgacioglu 2022.

Stakes

The absolute cancer burden HPV-naive catch-up vaccination is averting: lifetime US cervical-cancer risk ~0.6%, lifetime US oropharyngeal-cancer risk in men ~1.1% and rising Damgacioglu 2022, lifetime anal-cancer risk ~0.2% overall and dramatically higher in MSM. Genital-warts incidence is the most immediately felt downside: annual incidence ~1% in sexually active adults, painful biopsy or freeze-off treatments, recurrence common. The catch-up window's incremental benefit is genuinely smaller than vaccinating at 11 because much exposure has already happened — but it is not zero, and for the cancer endpoints with multi-decade latency (oropharyngeal in men in particular) much of the lifetime exposure is still ahead of the catch-up recipient.

Payoff

The genital-warts payoff lands fastest — vaccinated adults face essentially zero risk of new HPV-6/11 warts within weeks of completing the series, replicated across the Castellsague and Joura trials Castellsague 2011 Joura 2015. CIN3 (cervical pre-cancer requiring colposcopy and excision) reductions show up within 5–10 years in vaccinated cohorts Falcaro et al. 2021. Invasive cervical cancer reductions take 15–25 years to fully crystallise but show measurable population-level signal by 10–15 years Lei et al. 2020. Oropharyngeal cancer reductions in men will not show in registry data until the mid-2030s at earliest Damgacioglu 2022.

Practicalities

List price for Gardasil 9 in the US is ~$363 per dose, ~$1,089 for the three-dose series uninsured. Most commercial insurance covers it without copay; ACA preventive-care coverage is mandated through age 26 but variable in the catch-up band — the shared-decision-making framing means some payers cover and some require a clinical indication. Merck's patient assistance program supplies the vaccine free to uninsured adults aged 19–45 meeting income criteria. Logistically: three primary-care or pharmacy visits over 6 months; missed doses can resume without restart per ACIP catch-up guidance CDC 2024.

Failure modes

Most common: starting and not completing the three-dose series. Two doses confer substantially less protection than three in the catch-up age group (the two-dose schedule is only validated for ages 9–14, where immune response is stronger). Receiving the vaccine after established infection and assuming "now I'm covered" — the vaccine does not treat existing infection. Skipping cervical screening on the assumption that vaccination obviates it — Pap and HPV co-testing remain indicated regardless of vaccination status; non-vaccine types still cause cancer CDC 2024.

Alternatives

For HPV-related cancer prevention specifically in the catch-up window, the meaningful alternatives are continued cervical screening (does not prevent infection but catches pre-cancer early), barrier methods during new partner exposure (incomplete protection — HPV spreads via skin-to-skin contact outside condom coverage), and partner reduction. None of these is an HPV-vaccine substitute; they layer on top.

Out-of-scope

Adolescent routine vaccination (separate entry — different decision framing, much larger absolute benefit, ACIP universal recommendation). HPV vaccination in HIV-positive adults with established multi-type infection (Wilkin 2018 evidence does not support it for new infection prevention; clinical decision is different). Cervical cancer screening (Pap/HPV co-testing) and anal cancer screening in MSM are separate substances with their own evidence bases.

The credibility range

Optimist case

HPV vaccination is one of the most consistently positive trial programmes in modern preventive medicine: multiple RCTs of three vaccine generations, all positive on every prespecified endpoint, replicated in population registers across countries with mature programmes. Adult-trial data (Castellsague 2011 88.7% per-protocol; Joura 2015 96.7% for the added types) show the vaccine works at the same per-naive-encounter rate in 24–45-year-olds as in adolescents. Type-specific naivety remains common even in sexually experienced adults — most adults are still naive to most of the nine vaccine types. The vaccine prevents six cancers and a debilitating, costly sexually transmitted condition (warts) with a single course. Catch-up cost per QALY is favourable in subgroups with anticipated new exposure. The downside risk is bounded — three injection-site sore arms over six months.

Skeptic case

The catch-up trial (Castellsague) excluded women with prior cervical disease or warts — a substantially cleaner population than typical 35-year-olds. The intention-to-treat effect is much smaller than the per-protocol — ~47% vs 88.7% — because women with prevalent infection were enrolled but not protected from existing types Castellsague 2011. ACIP explicitly declined to recommend routine catch-up because the public-health benefit at the population level is "minimal" — most people in the 27–45 band have already been exposed to most HPV types they will encounter Meites 2019. The A5298 trial showed flat-zero benefit for new anal HPV in HIV-positive adults — the same population where you would predict highest baseline catch-up benefit by cancer-risk logic — which suggests cumulative exposure dominates in real-world catch-up populations Wilkin 2018. Direct invasive-cancer endpoints in catch-up-aged adults will not exist until the 2040s. The cost-effectiveness picture for routine adult catch-up is poor (US analyses estimate $300,000+ per QALY for routine vaccination of all 30–45-year-olds, vs. ~$25,000 per QALY for adolescents).

Author's call

The vaccine works in adults; the evidence is solid (Castellsague RCT plus consistent population data). The catch-up question is not "does it work" — it is "how big is my marginal benefit." For an unvaccinated adult under 45 with anticipated new partner exposure, or who is plausibly naive to most vaccine types, the upside is real and the downside is bounded. For a long-married 44-year-old with no expected new exposure, the marginal benefit is small enough that "decide with a clinician" is honest framing. This entry treats it as an action: decide — the reader gets the case framed, not a blanket "yes." ACIP's shared-decision-making language is the right epistemic level for catch-up. Evidence score 4; controversy 2 (real disagreement on cost-effectiveness and routine recommendation, no disagreement on whether the vaccine works).

Stakeholder + incentive map

Merck — the only US manufacturer of Gardasil 9. Strong commercial incentive to expand the catch-up age band; funded both the FDA approval submission and the post-2018 advertising push.
ACIP / CDC — public-health framing weights population-level cost-effectiveness. Their decline to recommend routine catch-up (vs shared decision-making) reflects this framing, not skepticism about the vaccine itself Meites 2019.
Specialty oncology and gynecology societies — generally favourable; see catch-up vaccination as a tool clinicians should be discussing.
Vaccine-skeptic community — has periodically highlighted (largely refuted) safety claims; the autoimmune-disease and POI signals investigated in large cohorts have not borne out.
Payers — coverage is variable in the 27–45 band; some require documented clinical indication. ACA preventive-care coverage applies through 26.

Population variability

Effect is largest in: type-naive adults, those with anticipated new partner exposure, MSM (highest baseline anal-cancer risk), women with low prior partner count, individuals about to undergo or following immunosuppression. Effect is smallest in: HIV-positive adults with established multi-type infection Wilkin 2018, long-term monogamous adults with no anticipated new exposure, and those with documented past infection by multiple vaccine types. Sex differences: the cervical-cancer prevention is the dominant per-dose benefit in women; the oropharyngeal-cancer prevention is the dominant emerging benefit in men but the time horizon is decades Damgacioglu 2022. Race and ethnicity: vaccine efficacy does not vary meaningfully; access and uptake do, with US Black and Hispanic adults historically under-vaccinated.

Knowledge gaps

Direct invasive-cancer endpoints in adults vaccinated at 27–45 will not be available until 2040+, because cervical and oropharyngeal cancer latency exceeds the trial follow-up. The trade-off between supplemental 9-valent vaccination of adults previously vaccinated with bivalent/quadrivalent is not directly addressed by trial data. The true population benefit of catch-up in the post-19-vaccine-coverage cohorts (i.e., 27-year-olds in 2030 who were eligible at 12 in 2015) is uncertain and may be very small. What would change the author's call: a positive RCT in HIV-negative immunocompetent adults aged 30–45 with direct cancer endpoints (likely never to be run); cost-effectiveness analyses that vary by partner-count subgroup; clear payer policy normalising coverage in the 27–45 band.

Scope match to brief. The brief named cervical, oropharyngeal, anal, "other HPV-related cancers," and genital warts. All five are covered in the body: cervical (evidence, payoff), oropharyngeal (stakes, payoff), anal (evidence — Palefsky 2011 callout, audience — MSM), "other" (vulvar, vaginal, penile noted in stakes), and warts (evidence, payoff). No silent narrowing.

Action choice: decide rather than do. ACIP's shared-clinical-decision-making framing is the right epistemic level for this age band — the marginal benefit varies sharply by anticipated future exposure. A blanket do would oversell to monogamous long-married readers; know would undersell to the readers for whom the math clearly works. The audience section names the subgroups for whom the answer leans yes.

Longevity score of 2. Score was the hardest call. The vaccine prevents six cancers — that pulls toward 3 or 4. But the catch-up window's marginal absolute reduction is meaningfully smaller than at age 11–12 (Lei 2020 shows the gradient clearly), and ACIP explicitly declined a routine catch-up recommendation on population-benefit grounds (Meites 2019). Landed at 2 — "small additive effect on mortality risk" — because that better matches the catch-up window's effect than 3 ("meaningful disease-prevention") does. The score reflects this entry's substance (catch-up at 27–45), not HPV vaccination in general.

Future-link candidates. Once written, this entry should cross-link to: (a) routine adolescent HPV vaccination, (b) cervical cancer screening (Pap/HPV co-testing), (c) anal cancer screening for high-risk groups. None exist yet in the catalogue.

Separate-entry candidates. Routine adolescent HPV vaccination is its own entry — different action (do, parental decision), much larger absolute benefit, ACIP universal recommendation, very different controversy profile (anti-vaccine politics around adolescent immunisation). HPV vaccination in HIV-positive adults is plausibly its own entry given the negative A5298 trial; flagged for later.

Cost score. Insurance variability makes the score honest at 2. Most insured adults pay $0; uninsured pay up to ~$1,089. The pitch leads with the uninsured number because that is what readers face when they call to book without checking coverage first.

Excluded from article. The HIV-positive catch-up question (Wilkin 2018) is referenced briefly in evidence and audience but not given its own section — readers in that population should be having a different conversation with their HIV specialist, not making a shared-decision call out of a general catalogue entry. The cost-effectiveness debate is in research (skeptic case) but kept out of the article — readers do not need the QALY math, just the framing of when the personal math leans yes.